Glycophos (Sodium Glycerophosphate Pentahydrate)

Glycophos is indicated for conditions where phosphate replenishment is required, particularly in hospitalized patients receiving intravenous therapy.

• Treatment of hypophosphatemia associated with acute or chronic illnesses.
• Phosphate replacement in total parenteral nutrition (TPN) formulations.
• Support of patients undergoing renal replacement therapy who develop phosphate loss.
• Management of phosphate depletion during prolonged fasting or severe malnutrition.
• Adjunctive therapy in critical care settings to maintain electrolyte balance.
• Correction of phosphate deficits prior to major surgical procedures.

Phosphate infusion may be associated with a range of adverse effects, most of which are related to the rate of administration and patient-specific factors.

Common

• Mild nausea or vomiting.
• Transient flushing or warmth at the infusion site.
• Temporary elevation of serum calcium levels.
• Mild headache or dizziness.
• Slight increase in serum potassium.
• Local irritation or pain at the injection site.

Serious

• Severe hyperphosphatemia leading to calcium‑phosphate precipitation.
• Acute respiratory distress due to pulmonary edema.
• Cardiac arrhythmias associated with electrolyte imbalance.
• Hypotension from rapid infusion.
• Allergic reactions such as urticaria or anaphylaxis.
• Renal failure exacerbation due to phosphate overload.
• Metabolic acidosis in susceptible patients.

When prescribing Glycophos, clinicians should evaluate patient history and laboratory values to minimize the risk of complications.

• Verify baseline serum phosphate, calcium, and renal function before initiation.
• Adjust infusion rate to avoid rapid shifts in phosphate concentration.
• Use caution in patients with severe renal impairment or on dialysis.
• Monitor electrolytes regularly during therapy, especially calcium and magnesium.
• Avoid concurrent administration with calcium‑containing solutions in the same line.
• Consider dose reduction in patients with a history of hyperphosphatemia.
• Discontinue if signs of hypersensitivity or severe electrolyte disturbances develop.

Glycophos may interact with other intravenous agents or medications that affect electrolyte balance.

Avoid

• Simultaneous infusion with calcium gluconate or calcium chloride in the same line.
• Co‑administration with high‑dose vitamin D analogues that increase calcium absorption.
• Use with loop diuretics that promote calcium loss without monitoring.

Use with caution

• Concurrent use of bisphosphonates, which can alter phosphate metabolism.
• Administration alongside antacids containing aluminum or magnesium.
• Patients receiving insulin therapy, as insulin can shift phosphate intracellularly.
• Combination with other phosphate binders, requiring careful monitoring of serum levels.